Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: Evidence-based practice and best practices

Hematology/Oncology Clinics of North America

Volumn 25, Issue 4, 2011, Pages 893-915

  Appleby, Laurie ^a   Morrissey, Stephanie ^a   Bellmunt, Joaquim ^b   Rosenberg, Jonathan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Evidence based practice; MTOR inhibitor; Renal cell carcinoma; Treatment related toxicity; Tyrosine kinase inhibitor

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CLOTRIMAZOLE; COLESTYRAMINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENOXYLATE; EVEROLIMUS; FLUCONAZOLE; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIDOCAINE; LOPERAMIDE; LORAZEPAM; MEGESTROL ACETATE; METOCLOPRAMIDE; NITRATE; NYSTATIN; ONDANSETRON; PAZOPANIB; PROCHLORPERAZINE; PROTON PUMP INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANOREXIA; ANTIANGIOGENIC THERAPY; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG METABOLISM; DYSPEPSIA; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUNG FUNCTION TEST; METABOLIC SYNDROME X; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA AND VOMITING; PATIENT CARE; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; STOMATITIS; SUBUNGUAL HEMORRHAGE; SYSTEMIC VASCULAR RESISTANCE; TASTE; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT REFUSAL;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; DRUG TOXICITY; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960347553     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.05.004     Document Type: Review

References (96)

1. Bellmunt J., Eisen T., Fishman M., et al. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011, 78(1):24-32.
2. Bellmunt J., Montagut C., Albiol S., et al. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007, 99:274.
3. Canoy D., Luben R., Welch A., et al. Fat distribution, body mass index and blood pressure in 22,090 men and women in the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study. J Hypertens 2004, 22:2067.
4. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129.
5. Hood J.D., Meininger C.J., Ziche M., et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998, 274:H1054.
6. Horowitz J.R., Rivard A., van der Zee R., et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997, 17:2793.
7. Robinson E.S., Khankin E.V., Choueiri T.K., et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010, 56:1131.
8. Vaklavas C., Lenihan D., Kurzrock R., et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 2010, 15:130.
9. Di Lorenzo G., Autorino R., Bruni G., et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009, 20:1535.
10. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206.
11. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48:9.
12. Wu S., Chen J.J., Kudelka A., et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:117.
13. Ranpura V., Pulipati B., Chu D., et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010, 23:460.
14. Rini B.I. Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 2010, 8:415.
15. Rixe O., Billemont B., Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007, 18:1117.
16. Izzedine H., Ederhy S., Goldwasser F., et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807.
17. Langenberg M.H., van Herpen C.M.L., De Bono J., et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 2009, 27:6152.
18. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1.
19. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560.
20. Miura S., Fujino M., Matsuo Y., et al. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 2005, 28:147.
21. Ranpura V., Hapani S., Chuang J., et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010, 49:287.
22. Schutz F.A., Je Y., Azzi G.R., et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011, 22(6):1404-1412.
23. Nalluri S.R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300:2277.
24. Choueiri T.K., Schutz F.A., Je Y., et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280.
25. Deuse T., Peter C., Fedak P.W., et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009, 120:S247.
26. Giordano F.J., Gerber H.P., Williams S.P., et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001, 98:5780.
27. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204.
28. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16.
29. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516.
30. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115.
31. Khakoo A.Y., Halushka M.K., Rame J.E., et al. Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2005, 2:53.
32. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757.
33. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500.
34. Telli M.L., Witteles R.M., Fisher G.A., et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19:1613.
35. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378.
36. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125.
37. Kane R.C., Farrell A.T., Saber H., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271.
38. Choueiri T.K., Mayer E.L., Je Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011, 29(6):632-638.
39. Hapani S., Sher A., Chu D., et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27.
40. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967.
41. Pouessel D., Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008, 53:376.
42. Porta C., Imarisio I., Paglino C. Re: Damien Pouessel, Stephane Culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008, 53:1092.
43. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271.
44. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449.
45. Agostino N., Chinchilli V.M., Lynch C.J., et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2010, [Epub ahead of print]. 10.1177/1078155210378913.
46. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110:227.
47. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061.
48. Miyake H., Kurahashi T., Yamanaka K., et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 2010, 28:515.
49. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81.
50. Wolter P., Stefan C., Decallonne B., et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008, 99:448.
51. Zhu X., Wu S., Dahut W.L., et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186.
52. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422.
53. Wu S., Kim C., Baer L., et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010, 21:1381.
54. Autier J., Escudier B., Wechsler J., et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008, 144:886.
55. Chu D., Lacouture M.E., Weiner E., et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009, 7:11.
56. Lacouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001.
57. Rosenbaum S.E., Wu S., Newman M.A., et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008, 16:557.
58. Porta C., Paglino C., Imarisio I., et al. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007, 7:127.
59. Lee W.J., Lee J.L., Chang S.E., et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009, 161:1045.
60. Hutson T.E., Figlin R.A., Kuhn J.G., et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13(10):1084-1096.
61. Beldner M., Jacobson M., Burges G.E., et al. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007, 12:1178.
62. Lacouture M.E., Reilly L.M., Gerami P., et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008, 19:1955.
63. Schwandt A., Wood L.S., Rini B., et al. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2009, 2:51.
64. Michaelson M, Cohen D, Li S, et al. Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). In American Society of Clinical Oncology: Genitourinary Cancers Symposium. Orlando (FL), February 17-19, 2011.
65. Bellmunt J., Szczylik C., Feingold J., et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008, 19:1387.
66. Alexandrescu D.T., Vaillant J.G., Dasanu C.A. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007, 32:71.
67. Wood L. Managing the side effects of sunitinib and sorafenib. Community Oncol 2006, 3:558.
68. Rodriguez-Pascual J., Cheng E., Maroto P., et al. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 2010, 21:478.
69. Schmidinger M., Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010, 36:416.
70. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182:396.
71. Cramer J., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44.
72. Yavuzsen T., Davis M.P., Walsh D., et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005, 23:8500.
73. Bhojani N., Jeldres C., Patard J.-J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53:917.
74. Everolimus 2009, [package insert], Novartis Pharmaceuticals, East Hanover, NJ.
75. Pazopanib 2009, [package insert], GlaxoSmithKline, Research Triangle Park, NC.
76. Sorafenib [package insert]. West Haven, CT and Emeryville, CA; Bayer Pharmaceutical Corporation and Onyx Pharmaceuticals, Inc.; 2006.
77. Pazopanib 2006, [package insert], Pfizer Labs, New York, NY.
78. Temsirolimus 2010, [package insert], Wyeth Pharmaceuticals, Inc, Philadelphia, PA.
79. Mansky P.J., Wallerstedt D.B. Complementary medicine in palliative care and cancer symptom management. Cancer J 2006, 12:425.
80. Wood L.S. Management of vascular endothelial growth factor and multikinase inhibitor side effects. Clin J Oncol Nurs 2009, 13(Suppl):13.
81. Peterson D.E., Bensadoun R.J., Roila F., et al. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 2009, 20:174. On behalf of the EGWG.
82. Larkin J.M., Pyle L.M., Gore M.E. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist 2010, 15:1135.
83. Wang X.S. Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs 2008, 12:11.
84. McNeely M.L., Courneya K.S. Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J Natl Compr Canc Netw 2010, 8:945.
85. Ernst E. Massage therapy for cancer palliation and supportive care: a systematic review of randomised clinical trials. Support Care Cancer 2009, 17:333.
86. Minton O., Richardson A., Sharpe M., et al. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 2011, 41(4):761-767.
87. Haoualaa A., Widmer N., Buclin T., et al. Cardiovascular drug interactions with tyrosine kinase inhibitors. Cardiovasc Med 2010, 13:147.
88. Horn J., Hansten P. Drug interactions with tyrosine kinase inhibitors Available at:, Accessed February 5, 2011. http://www.pharmacyTimes.com.
89. Moore S. Adherence to oral therapies for cancer: barriers and models for change. Journal of the Advanced Practitioner in Oncology 2010, 1:155.
90. Weingart S., Brown E., Bach P., et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008, 6:s1.
91. Partridge A.W., Winer P.S., Avorn E.P. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21:602.
92. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487.
93. Blasdel C., Bubalo J. Adherence to oral cancer therapies: meeting the challenge of new patient care needs Available at:, Accessed February 5, 2011. http://www.clinicaloncology.com/download/563SR-Novartis.pdf.
94. Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs 2007, 30:112.
95. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56.
96. Viele C. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 2007, 64:S25.